<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>读书 on Illiterate&#39;s blog</title>
    <link>https://blog.illiterate.info/tags/%E8%AF%BB%E4%B9%A6/</link>
    <description>Recent content in 读书 on Illiterate&#39;s blog</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 05 Mar 2021 15:50:26 +0800</lastBuildDate><atom:link href="https://blog.illiterate.info/tags/%E8%AF%BB%E4%B9%A6/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Chapter 1 Drug Development Perspective</title>
      <link>https://blog.illiterate.info/posts/ch1_the-development-of-a-drug-a-pharmaceutical-drug-development-perspective/</link>
      <pubDate>Fri, 05 Mar 2021 15:50:26 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch1_the-development-of-a-drug-a-pharmaceutical-drug-development-perspective/</guid>
      <description>Critical steps enabling early development Reducing attrition biomedical approaches
  leverage pre-existing information including bioinformatics approaches
  integrating non-clinical information to predict clinical properties of NME
  optimize the operational costs to gain timely information in early trials
  non-clinical pharmacokinetic (PK) studies   PK profile in animals is first used to optimize subsequent formulation
  support non-clinical pharmacology and toxicology studies
  pharmacokinetic/pharmacodynamic (PK/PD) models to design</description>
    </item>
    
  </channel>
</rss>
